期刊文献+

ERCC1基因多态性与肝癌患者易感性分析 被引量:1

The relationship on polymorphisms of ERCC1-4533/8092 and the susceptibility of hepatocellular carcinoma
下载PDF
导出
摘要 目的探讨切除修复交叉互补基因1(ERCC1)-4533/8092位点单核苷酸多态性(SNPs)与广西壮族人群肝癌易感性之间关系。方法通过聚合酶链反应限制性片段长度多态性(PCR-RFLP)方法检测88例原发性肝癌患者和82例健康对照者的ERCC1-4533/8092基因多态性。结果 ERCC1-4533位点的基因分型在病例组和对照组的频数分布差异无统计学意义(P〉0.05),ERCC1-8092位点的基因分型在病例组和对照组的频数分布差异具有统计学意义(P〈0.05)。与携带ERCC1-8092CC基因型的个体相比,携带ERCC1-C8092CA/AA基因型的个体具有更高的肝癌易感性(CA:OR=2.556,95%CI:1.345~4.855;AA:OR=8.667,95%CI:1.000~75.092)。以携带ERCC1-8092C等位基因作为参照,携带ERCC1-C8092A等位基因可以增加原发性肝癌的发病危险性(OR=2.387,95%CI:1.428~3.992)。结论 ERCC1-8092位点基因多态性与广西壮族人群肝癌易感性有关。 Objective To investigate the relationship on the excision repair cross complementing gene 1(ERCC1)-4533/8092 site single nucleotide polymorphisms(SNPs)and the susceptibility to hepatocellular carcinoma(HCC)in Guangxi Zhuang population.Methods Polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP)method was used to detect the ERCC1-4533/8092 gene polymorphism in 88 cases with primary liver cancer and 82 cases of normal controls.Results There was no difference in the frequency distribution of ERCC1-4533 in the case group and the control group,the frequency distribution of the ERCC1-8092 in the case group and the control group was different(P〈0.05).Compared with ERCC1-8092 CC,ERCC1-C8092CA/AA had higher risk of primary hepatocellular carcinoma(CA:OR=2.556,95%CI:1.345-4.855;AA:OR=8.667,95%CI:1.000-75.092).ERCC1-8092 Callele as a reference,ERCC1-8092 Aallele can increase the risk of primary liver cancer(OR=2.387,95%CI:1.428-3.992).Conclusion The genetic polymorphisms of ERCC1-8092 sites are associated with susceptibility to hepatocellular carcinoma in Guangxi Zhuang population.
出处 《国际检验医学杂志》 CAS 2016年第18期2523-2525,共3页 International Journal of Laboratory Medicine
基金 广西自然科学基金资助项目(2012GXNSFAA053170)
关键词 ERCC1 原发性肝癌 基因多态性 易感性 ERCC1 primary hepatocellular carcinoma polymorphisms susceptibility
  • 相关文献

参考文献15

  • 1Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma Chemoemboli- zation improves survival [J]. Hepatology, 2003, 37 (2): 429-442.
  • 2朱薇,葛君琍,张利强,高海锋,赵秋剑.AFP、CEA、CA199、CA-125联合检测对肝癌、肝硬化诊断的临床价值[J].国际检验医学杂志,2012,33(15):1902-1904. 被引量:17
  • 3Gao H,Ge RC,Liu HY,et al. Effect of ERCC1 polymor- phism on the response to chemotherapy and clinical out- come of non-small cell lung cancer[J]. Genetics and Mo- lecular Research, 2014,13 (4) : 8997-9004.
  • 4Ueda S, Shirabe K, Morita K, et at. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellu- lar carcinoma[J]. Ann Surg Oneol, 2011, 18 (4) .. 1204- 1211.
  • 5Niedernhofer LJ, Odijk H, Budzowska M, et al. The struc- ture-specific endonuclease Erccl-Xpf is required to resolve DNA inter strand cross-link-induced double-strand breaks [J]. Mol Cell Bion, 2004,24 (13) : 5776-5787.
  • 6Metzger R. Pharmacogenetics and the practice of medicine [J]. Nature,2003,405 : 857-865.
  • 7王敬慧,张权,张卉,王群慧,杨新杰,顾艳斐,张树才.ERCC1基因多态性与晚期非小细胞肺癌患者铂类化疗疗效的关系[J].中国肺癌杂志,2010,13(4):337-341. 被引量:11
  • 8蓝永洪,郑小桃,蔡望伟,周代锋,林琼莲.海南人群中人类ERCC1-4533G/A多态性的研究[J].中国热带医学,2006,6(8):1377-1378. 被引量:2
  • 9Westerveld A, Hoeijmakers J H, van Duin M, et al. Molec- ular cloning of a human DNA repair gene[J]. Nature, 1984,310(5976) :425-429.
  • 10van Duin M,de Wit J,Odijk H,et al. Molecular character- ization of the human excision repair gene ERCC 1 : eDNA cloning and amino acid homology with the yeast DNA re- pair gene RADI0[J]. Cell, 1986,44(6) :913-923.

二级参考文献60

  • 1袁芃,缪小平,张雪梅,王中华,谭文,张湘茹,孙燕,徐兵河,林东昕.核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系[J].癌症,2005,24(12):1510-1513. 被引量:46
  • 2Nattiya Hirankarn,Ingorn Kimkonq,Pittaya Kummee,Pisit Tanqkijyanich,Yong Poovorawan.Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection[J].World Journal of Gastroenterology,2006,12(5):776-779. 被引量:14
  • 3廖维甲,梅铭惠,覃理灵.联合检测AFP与ICAM-1在原发性肝癌根治性切除术后复发的意义[J].现代检验医学杂志,2007,22(4):83-84. 被引量:3
  • 4Tabaldi C, Tibaldi C, Giovannetti E, et al. Correlation of CDA, ERCC 1, and XPD polymorphisms with response and survival in gemcitabine/cisplatintreated advanced non-small cell lung cancer patients. Clin Cancer Res, 2008, 14(6): 1797-1803.
  • 5De las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small- cell lung cancer patients. Ann Oncol, 2006, 17(4): 668-675.
  • 6Zhou W, Gurubbagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non- small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res, 2004, 10(15): 4939-4943.
  • 7Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 2007, 56(2): 281-288.
  • 8Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC 1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 2004, 44(3): 311-316.
  • 9Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol, 2004, 15(8): 1194-1203.
  • 10Kalikaki A, Kanald M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer, 2009, 10(2): 118-123.

共引文献63

同被引文献14

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部